Floxavid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Floxavid

Property Description
Active ingredient Ofloxacin (INN)
Form Tablets, Sterile Solution (IV, Ophthalmic, Otic)
Pharmacological class Fluoroquinolone Antibiotic
Common use Broad-spectrum anti-infective treatment
Origin Synthetic

Floxavid is a medicinal product defined by its active pharmaceutical ingredient, Ofloxacin, which is a high-potency, synthetic compound. This drug is classified as a prescription-only medication belonging to the fluoroquinolone antibiotic class of antimicrobial agents.

Floxavid: Active Ingredient, Origin, and Pharmacological Class

The core component of Floxavid is Ofloxacin (INN), a compound structurally derived from the quinolone family, specifically defined as a fluorinated carboxyquinolone. Ofloxacin is chemically a racemate, a mixture comprising the biologically active L-isomer (Levofloxacin) and the largely inactive D-isomer.

Floxavid’s General Function as a Bactericidal Agent

The primary function of Floxavid is to serve as a broad-spectrum anti-infective treatment aimed at the elimination of susceptible bacterial infections. This drug is clinically recognized for its bactericidal effect, meaning it actively kills the target bacteria rather than merely inhibiting their growth. This action involves the specific inhibition of essential bacterial enzymes, namely DNA gyrase (Topoisomerase II) and Topoisomerase IV, thereby halting the critical processes of DNA replication, transcription, and repair necessary for bacterial survival.

Available Forms and Routes of Administration

The active ingredient, Ofloxacin, is engineered into multiple pharmaceutical preparations to facilitate both systemic and localized treatment. Floxavid is commonly supplied as a single-ingredient formulation in tablets for oral administration and as a sterile solution for intravenous (IV) infusion for systemic use. A distinctive feature is its formulation into topical solutions, specifically as ophthalmic solutions (eye drops) and otic solutions (ear drops), allowing for the direct, high-concentration delivery necessary to treat localized infections.

Regulatory References

  1. DNA gyrase (Topoisomerase II) and Topoisomerase IV

What side effects are possible with Floxavid?

Possible side effects and safety information

The safety profile for Floxavid (Ofloxacin) is organized by government regulatory agencies based on the physiological systems affected and the estimated frequency of occurrence, with specific emphasis on serious adverse reactions and risks in particular patient groups.

Adverse Reaction Scope

Key Adverse Reaction Categories: Adverse effects are classified by the System-Organ Classes (SOCs) they affect, including Musculoskeletal and Connective Tissue Disorders, Nervous System Disorders (Central and Peripheral), Psychiatric Disorders, and Gastrointestinal Disorders.

Frequency Classification: Reactions are formally categorized using regulatory frequency tiers: Common reactions often include gastrointestinal upset (e.g., nausea, diarrhea) and minor central nervous system effects (e.g., headache, dizziness, insomnia). Rare and Very Rare classifications cover less frequent but more significant events, such as tendon disorders and severe liver damage. The Not Known category includes serious post-marketing risks such as aortic aneurysm/dissection and potentially irreversible peripheral neuropathy.

Serious Adverse Reactions (as documented in regulatory sources): Official labeling documents critical, potentially disabling, or irreversible events. These include Tendinitis and Tendon Rupture (may occur within hours or months after treatment cessation), Peripheral Neuropathy (nerve damage in hands/feet), severe CNS Effects (e.g., seizures, confusion, suicidal thoughts), and Dysglycemia (severe hypo- or hyperglycemia) [1.1, 2.3, 2.4].

Population-Specific Safety Considerations: Regulatory documents identify heightened risk in certain patient groups. Older Adults and patients receiving Systemic Corticosteroids are at an increased risk of tendon disorders and aortic aneurysm/dissection. Use in Pediatric Patients is generally not established due to concerns over effects on developing cartilage [1.6, 2.3, 2.7].

Safety-Related Restrictions: Caution is officially advised for patients with a history of CNS disorders (e.g., epilepsy) that may predispose them to seizures. Patients must also avoid unnecessary or prolonged sunlight and UV light exposure due to the risk of photosensitivity [1.1, 2.4].


Connection to the Overall Safety Profile

The official safety information strictly defines the potential risks using government-mandated classifications, which informs the understanding of the drug's risk profile separate from its therapeutic benefits. This regulatory framework emphasizes potentially disabling effects on the musculoskeletal and nervous systems and identifies specific population-based risk increases, providing a factual basis for risk assessment.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Floxavid overdose focuses on the potential for severe neurological and systemic toxicity resulting from high-dose exposure.

Element Official Regulatory Documentation
Documented Manifestations CNS effects including confusion, drowsiness, dizziness, and slurred speech. Gastrointestinal effects such as nausea are also documented.
Life-Threatening Outcomes Severe consequences may include seizures and loss of consciousness, particularly associated with profound hypoglycemia. Serious events such as aortic dissection or aneurysm are also noted as outcomes requiring urgent care.

When Immediate Medical Help is Required

The official instruction is to seek immediate medical help by calling emergency services for life-threatening symptoms. This action is mandated for manifestations such as seizures, loss of consciousness, or sudden, severe pain in the abdomen, chest, or back (potential sign of an aortic event).

Overdose Management and Considerations

Overdose exposure is managed with symptomatic and supportive treatment. No specific antidote is formally documented in regulatory labeling. Careful monitoring of blood glucose levels and EKG monitoring may be required during observation. Regulators highlight increased risk of severe hypoglycemia for elderly patients and those with diabetes in the event of overexposure.


Connection to the official overdose profile

Regulatory documents define the overdose profile based on the potential for acute CNS and metabolic toxicity, which dictates the conditions under which emergency medical help must be sought. This information specifies that life-threatening symptoms require immediate action, exactly as stated in the official prescribing instructions.

Therapeutic Uses of Floxavid

What Floxavid Treats: Main Uses and Benefits

Floxavid is a prescription medication used to help manage symptoms related to susceptible bacterial infections, applied across domains where additional symptomatic support is needed. As a formulation of Ofloxacin, it is considered relevant for a wide range of bacterial conditions.

This medication helps address symptom clusters that may become intense or disruptive in conditions such as urinary tract infections (UTIs), specific forms of pneumonia and bronchitis, skin and soft tissue infections, pelvic inflammatory disease (PID), and localized infections of the eye and ear. It is applied in clinical settings that involve acute or unstable symptom patterns.

“Floxavid is relevant for managing symptoms that interfere with daily comfort in situations where patients experience bacterial colonization.”

By addressing the susceptible bacterial presence, Floxavid supports the patient during difficult symptomatic episodes. This action contributes to easing the overall symptom load and may assist with maintaining functional stability during periods of heightened physical discomfort.

Quick Fact: Relief for Acute Discomfort
Floxavid is commonly used to help with acute, disruptive symptoms like painful urination (dysuria) in UTIs and local pain/discharge in ophthalmic or otic infections.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Floxavid (Ofloxacin) eligibility is determined by official regulatory documents based on patient age, medical history, and physiological status.

Contraindicated Populations

Use of Floxavid is absolutely contraindicated in patients with a history of hypersensitivity to ofloxacin or any other medicine in the quinolone or fluoroquinolone class. It must also be avoided in patients with a known history of myasthenia gravis (due to the risk of muscle weakness exacerbation) and in those with a history of tendinitis or tendon rupture associated with previous fluoroquinolone use.

Age-Related Restrictions

Systemic use (oral/intravenous) is generally contraindicated in children and growing adolescents, as the safety and efficacy have not been established in this pediatric population. Topical use (eye/ear drops) is permitted for certain indications in patients typically 6 months or 1 year of age and older. Geriatric patients (over 60 years) require caution due to an increased risk of tendon problems.

Conditional Use and Comorbidity Rules

Use is restricted or requires caution in patients with impaired renal function, CNS disorders (e.g., epilepsy), or specific cardiac risk factors (e.g., QT prolongation). Pregnancy and lactation status often lead to contraindicated status for systemic use, as stated in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Floxavid (ofloxacin) as established by government regulatory agencies.


Interaction Scope

Property Detail
Medicinal product categories with documented interactions Antacids (Aluminum, Magnesium, Calcium), Sucralfate, Mineral Supplements (Iron, Zinc), Didanosine, Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Drugs that Prolong the QT Interval, Oral Hypoglycemic Agents/Insulin, Vitamin K Antagonists.
Specific interacting medicines (if explicitly listed) Cimetidine, Probenecid, Furosemide, Methotrexate, Theophylline, Fenbufen, Glibenclamide, Warfarin.
Mechanistic basis of interactions (only if stated in label) Chelation: The formation of complexes with polyvalent metal cations substantially interferes with Floxavid's absorption, leading to reduced systemic exposure. Renal Tubular Competition: Competition for active transport during renal excretion reduces Floxavid's clearance and increases its serum levels. Pharmacodynamic: Additive effects that potentiate anticoagulant effects or lower the cerebral seizure threshold.
Timing-based interaction rules Oral Floxavid must not be taken within the two-hour period before or within the two-hour period after administration of cation-containing antacids, sucralfate, iron, or zinc preparations.
Population-specific interaction notes The risk of tendinitis and tendon rupture when co-administered with corticosteroids is increased in patients over 60 years of age. Close monitoring of blood glucose is recommended for diabetic patients treated with oral hypoglycemic agents like Glibenclamide.
Interaction-related restrictions Co-administration with corticosteroids increases the risk of tendinitis/rupture. The increase in anticoagulant effect with Warfarin requires coagulation test monitoring ( PT/ INR).

Official Interaction Statements

  • Co-administration of agents containing polyvalent cations (e.g., iron, aluminum, magnesium, zinc) or Sucralfate significantly reduces Floxavid absorption, necessitating timed separation.
  • Co-administration with Theophylline or NSAIDs (e.g., Fenbufen) may result in a pronounced lowering of the cerebral seizure threshold.
  • Drugs such as Probenecid and Cimetidine decrease Floxavid's clearance, which increases the drug's systemic exposure.
  • Concurrent use with corticosteroids increases the risk of tendon problems.
  • Floxavid may increase the effect of Vitamin K antagonists, requiring monitoring of coagulation parameters.

Connection to the overall interaction profile

Official regulatory documents define the interaction structure around three primary constraints: the necessity of timed separation due to chelation, the risk of additive toxicities with agents affecting the central nervous system or QT interval, and the requirement for enhanced patient monitoring due to pharmacodynamic potentiation with anticoagulants and oral hypoglycemic agents. This profile establishes a set of explicit rules and vigilance requirements based on documented pharmacokinetic and pharmacodynamic outcomes.

Mechanism of Action

How Floxavid Works: Mechanism of Action

Floxavid's mechanism operates by interfering with bacterial genetic maintenance processes.

Targeting Key Bacterial Replication Enzymes

Floxavid's primary action involves acting as an inhibitor on two essential bacterial enzymes: DNA Gyrase and Topoisomerase IV. By binding to and stabilizing the enzyme-DNA complex, the drug interrupts the structural processes required for bacterial genetic integrity. The mechanism acts preferentially on the bacterial forms of these enzymes rather than their human counterparts; this differential binding is based on structural differences between prokaryotic and eukaryotic enzymes.

Disrupting the DNA Replication and Repair Cascade

This intervention modifies early molecular steps, specifically by preventing the necessary unwinding, copying, and separation of the bacterial DNA. This disruption initiates a failed cascade of stress and repair, which leads directly to the termination of bacterial life processes (bactericidal action). The resulting physiological modulation is the reduction of the specific bacterial population susceptible to the drug's mechanism.

Dosage and Administration Information

General Administration Guidelines

Floxavid is an oral medication that should be taken according to the specific schedule provided by a healthcare professional. To maintain a consistent level of the medication in the bloodstream, it is generally recommended to take the doses at evenly spaced intervals throughout the day and night.

Practical Considerations for Intake

The medication can be taken regardless of food intake. Patients may choose to take it with or without a meal. For individuals who experience gastrointestinal discomfort when taking medications, consuming it alongside a meal may help improve tolerance.

Consistency and Continuity

It is important to continue the full course of the medication as discussed with a provider. The duration of use is determined based on the nature of the condition being addressed. Maintaining the schedule helps ensure the medication functions as intended.

Fluid Intake

Adequate hydration is often encouraged while taking medications in this class. Patients should consume a sufficient amount of water throughout the day unless otherwise advised by a medical professional.

Recent Clinical Evidence

Research evidence / Overview of studies for Floxavid

Research for Conditions Characterized by Fluctuating or Episodic Manifestations

Floxavid was studied for conditions characterized by fluctuating or episodic manifestations. The research was used in studies exploring how symptoms change over time and was applied in research contexts involving fluctuating or unstable symptoms. These trials were relevant in trials assessing short-term or episodic symptom patterns, as well as in observational settings evaluating daily-life functioning.

Studies monitored outcomes reflecting daily functioning or activity level. Studies examined outcomes related to symptom intensity or variability in the observed populations. These findings describe patterns observed in the studies and help contextualize how patients reported their experience when symptoms may vary in intensity.

However, evidence indicates that follow-up durations were limited in initial studies. While findings describe group patterns, data are still emerging regarding long-term effects, and certainty remains low for outcomes beyond a defined time interval. The evidence quality varies across studies, and results apply only to the populations studied. Evidence also highlights that the relevance of some comparative findings may be affected by the increasing prevalence of bacterial resistance over time.

Outcomes Related to Physical Discomfort

Research focusing on episodes where symptoms become more noticeable specifically explored outcomes related to physical discomfort. Research describes how the product was evaluated in contexts involving fluctuating or unstable symptoms. Studies observed patterns related to outcomes linked to inflammatory or irritative states; studies reported how symptoms evolved in the observed populations. Subgroup findings are uncertain, and data for certain groups remain insufficient.

Research for Conditions Associated with Acute or Disruptive Episodes

Floxavid was studied for conditions associated with acute or disruptive episodes. These studies explored short-term symptom changes, with research examining outcomes related to physical discomfort during phases of heightened symptom activity. The evidence derived from settings with varying symptom burdens was evaluated in contexts of temporary physiological imbalance.

Studies monitored how outcomes related to systemic or functional imbalance evolved in the observed populations over defined time intervals. Research reports changes measured during the study period; studies explored symptom patterns related to physiological strain or stress. Comparative evidence is lacking, and data for certain groups remain insufficient.

Research in Older Adult Populations

Studies exploring the use of Floxavid in older adults was observed in some research settings. Sample sizes were modest in these specific trials, and the results apply only to the populations studied. There is limited information for long-term outcomes in this specific group. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Overall, the research provides context but not individual predictions. Findings describe group patterns, not personal outcomes, and the evidence highlights what is known—and what is still uncertain—about Floxavid.

Key Studies & References

  1. A systematic review of the effectiveness of ofloxaxin otic solution for the treatment of suppurative otitis media

Frequently Asked Questions (FAQ)

Common questions about Floxavid (FAQ)


Q: How quickly does Floxavid start working after the first dose?

According to official regulatory documents, the maximum concentration of Floxavid in the bloodstream is typically reached within one to two hours after a person takes an oral dose. This time point represents when the drug has been absorbed and is available to begin its systemic action.


Q: How long do the effects of Floxavid typically last?

Official information describes the drug's plasma half-life—the time it takes for the concentration to reduce by half—as approximately four to five hours in younger subjects. Most of the administered drug is generally described as being excreted from the body via the kidneys within 48 hours.


Q: Do I need to stop taking my other vitamins or supplements while on Floxavid?

The official administration guidelines require that oral Floxavid must be taken at least two hours apart from any products containing polyvalent metal cations. This primarily includes supplements containing minerals like iron, aluminum, or magnesium, because these substances are described as interfering with the drug's absorption into the body.


Q: Are there any specific foods or drinks that should be avoided when using Floxavid?

Official documentation states that Floxavid tablets can be taken either with or without food. The main requirement for avoidance is separating the dose from products that contain multivalent metal cations, which are often found in certain mineral supplements or antacids, as this interference reduces the drug's absorption.


Q: Does Floxavid cause drowsiness or make it difficult to drive?

Floxavid is known to cause central nervous system (CNS) effects, such as dizziness or lightheadedness, which are listed in regulatory documents. Because of this possibility, regulatory guidance describes that patients should be aware of how the drug affects their reaction and alertness before driving or operating complex machinery.


Q: What are the most common but mild side effects reported for Floxavid?

According to the official safety profile, common reactions often reported include temporary gastrointestinal upset, such as nausea and diarrhea. Minor central nervous system effects are also common, which can include feeling dizzy, having a headache, or experiencing trouble sleeping.


Q: Are there any known interactions between Floxavid and common pain relievers like ibuprofen?

Official regulatory documents list Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a category which includes drugs like ibuprofen, as a class of interacting medicine. Co-administration with Floxavid is described as potentially increasing the risk of central nervous system stimulation.


Q: How is the use of Floxavid described for people with diabetes?

Floxavid is associated with a risk of severe dysglycemia—unusually high or low blood sugar levels—as noted in the official warnings. Regulatory agencies recommend close monitoring of blood glucose for diabetic patients, particularly those who are treated with oral hypoglycemic agents.


Q: How long after stopping Floxavid do the drug's effects leave the body?

The speed at which Floxavid is cleared from the body is generally measured by its half-life, which is about four to five hours. Most of the administered dose is described as being excreted via the kidneys within 48 hours after the last dose is taken.


Q: What happens if I forget to take a dose of Floxavid?

Official regulatory instructions for a missed dose state that it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and taking a double dose to make up for the missed one is generally not recommended in the official instructions.


Q: Is it normal to feel a mild headache when first starting Floxavid?

Headache is documented in official safety information as a common reaction to Floxavid. Central nervous system (CNS) effects are described as potentially beginning as soon as after the first dose is administered.


Q: What is the risk of an allergic reaction to Floxavid?

Serious allergic reactions, or hypersensitivity, are documented in the official safety warnings for Floxavid. These reactions can occur even after a single dose. Regulatory documents describe severe reaction symptoms as requiring immediate attention.


Q: Is Floxavid safe for people with known heart conditions?

Official warnings advise caution for individuals who have certain cardiac risk factors, such as known QT prolongation or uncorrected electrolyte imbalances. In some specific cases, regulatory documents note that ECG monitoring may be necessary during treatment.


Q: Can Floxavid interfere with the results of lab tests, like blood work?

Official regulatory information describes that Floxavid has been shown to potentially interfere with specific laboratory screening tests, such as the test for urinary porphyrins. This interference may result in a false-positive reading for that particular lab test.


Q: Are there different brand names for the same medicine as Floxavid?

Yes, the active ingredient in Floxavid, Ofloxacin, is manufactured under various brand names depending on the specific formulation and location. Examples of brand names listed in public health databases include Floxin for oral tablets and Floxin Otic for the ear solution.


Q: What is the research evidence basis for using Floxavid in children?

Systemic use (oral or intravenous) of Floxavid is generally contraindicated because its safety and efficacy have not been established in children or growing adolescents. However, the use of topical solutions (eye or ear drops) is permitted for specific indications in patients typically aged 6 months or one year and older, based on specific established data.

How should Floxavid be stored and disposed of?

The storage and disposal of Floxavid (ofloxacin) must adhere to specific conditions mandated in official regulatory labeling.


Storage Conditions

Floxavid tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The medicine must be kept in a tightly closed container and protected from excessive heat, moisture, direct light, and it must keep from freezing. Floxavid must be stored in a secure location that is out of the reach of children.


️ Disposal Instructions

Unused or expired Floxavid should be discarded using a community-based drug take-back program. If a take-back option is unavailable, the medicine may be placed in the household trash after being mixed with an unappealing substance, such as dirt or used coffee grounds, and sealed in a container. The medicine must not be flushed down the toilet or poured into wastewater unless specifically directed by the official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Floxavid found in:

A-Z Index: